Abstract

Nanoparticles (NPs) are developed for many applications in various fields, including nanomedicine. The NPs used in nanomedicine may disturb homeostasis in blood. Secondary hemostasis (blood coagulation) and fibrinolysis are complex physiological processes regulated by activators and inhibitors. An imbalance of this system can either lead to the development of hemorrhages or thrombosis. No data are currently available on the impact of NPs on fibrinolysis. The objectives of this study are (1) to select a screening test to study ex vivo the impact of NPs on fibrinolysis and (2) to test NPs with different physicochemical properties. Euglobulin clot lysis time test was selected to screen the impact of some NPs on fibrinolysis using normal pooled plasma. A dose-dependent decrease in the lysis time was observed with silicon dioxide and silver NPs without disturbing the fibrin network. Carbon black, silicon carbide, and copper oxide did not affect the lysis time at the tested concentrations.

Original languageEnglish
Article number317
JournalJournal of Nanoparticle Research
Volume17
Issue number7
DOIs
Publication statusPublished - 27 Jul 2015

Keywords

  • Blood
  • Fibrinolysis
  • Hemocompatibility
  • Nanomedicine
  • Nanoparticles

Fingerprint

Dive into the research topics of 'The euglobulin clot lysis time to assess the impact of nanoparticles on fibrinolysis'. Together they form a unique fingerprint.

Cite this